The journal's third 2026 editorial targets a sweeping OMB proposal to overhaul federal grantmaking — even as five researchers, including the Editor-in-Chief, are removed from the ADA's annual meeting.
Federal prosecutors allege that a Florida physician and research staff fabricated clinical trial records that were submitted into database systems used to evaluate investigational drugs.